ST. LOUIS, MO – January 17, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading physicians in inflammatory bowel disease (IBD) who will provide strategic input based on their deep scientific knowledge and clinical expertise. Together, they will guide Geneoscopy through the development of their RNA-based technology to assess stool samples for epithelial and immunological markers that may predict individual response to IBD therapeutics and improve monitoring of disease activity. 

“Establishing a Scientific Advisory Board focused on IBD is a significant step forward in our mission to transform GI health,” said Erica Barnell, MD, PhD, Chief Medical and Scientific Officer of Geneoscopy. “It is an honor to have such distinguished advisors to help us identify significant opportunities to advance methods for IBD diagnostics using our innovative RNA technology. Their valuable insights undoubtedly will enhance our endeavors to bring much-needed IBD management tools to patients and clinicians. ”

The five-member SAB includes:

Matthew A. Ciorba, MD (Chair), Professor of Medicine, Washington University School of Medicine

    • Director, Inflammatory Bowel Diseases Center
    • Director, IBD Research

Ashwin N. Ananthakrishnan, MD, MPH, Associate Professor of Medicine, Harvard Medical School

    • Director of the Crohn’s and Colitis Center at Massachusetts General Hospital

Marla C. Dubinsky, MD, Professor of Pediatrics and Medicine (Gastroenterology), Mount Sinai Medical Center

    • Chief, Division of Pediatric Gastroenterology at Mount Sinai Kravis Children’s Hospital
    • Co-Director, Susan and Leonard Feinstein Clinical IBD Center

Parambir S. Dulai, MD, Associate Professor of Medicine, Director of GI Clinical Trials and Precision Medicine, Feinberg School of Medicine Northwestern University

    • Division of Gastroenterology and Hepatology

Laura E. Raffals, MD, MS, Professor of Medicine, Mayo Clinic

    • Department of Medicine Associate Chair of Faculty Development
    • Vice Chair of the Division of Gastroenterology and Hepatology 

“Geneoscopy’s research efforts could not come at a better time. Nearly 1 out of every 100 Americans are diagnosed with IBD, and that number continues to grow. With many IBD therapies now available or in development, there is an important need for novel tools to help guide clinicians in therapy selection and disease monitoring,” noted Board Chair Matthew A. Ciorba, MD. “I am pleased to serve as Chair of this esteemed group of thought leaders as we help Geneoscopy to identify areas of unmet clinical need and assess the feasibility of applying Geneoscopy’s technology towards an IBD diagnostic product.”

About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing diagnostic tests for treatment selection and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit and follow the company on LinkedIn.

Geneoscopy Inc. Forward-Looking Statements

This release includes information about Geneoscopy’s future plans concerning its stool-based RNA biomarker platform and its potential application to IBD, which constitute forward-looking statements. These forward-looking statements are based on the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.

Geneoscopy’s Scientific Advisory Board members are compensated consultants. Their individual perspectives and opinions are based on personal experiences.

Media Contact
Andrea Sampson
Sampson Public Relations Group

Investor Contact
Carrie Mendivil / Ji-Yon Yi
Gilmartin Group